Home > Oncology > SABCS 2021 > Triple-Negative Breast Cancer > Neoadjuvant pembrolizumab plus chemotherapy benefits event-free survival in TNBC

Neoadjuvant pembrolizumab plus chemotherapy benefits event-free survival in TNBC

Presented By
Prof. Peter Schmid, Barts Cancer Institute, UK

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
SABCS 2021
Trial
Phase 3, KEYNOTE-522
Primary analysis of the KEYNOTE-522 trial showed a statistically significant and clinically meaningful improvement in the event-free survival (EFS) of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab versus neoadjuvant chemotherapy alone, in patients with early triple-negative breast cancer (TNBC). Pembrolizumab showed anti-tumour activity and manageable safety in metastatic TNBC [1,2]. In addition, results from the phase 1b KEYNOTE-173 trial (NCT02622074) showed that pembrolizumab plus neoadjuvant chemotherapy had promising anti-tumour activity and manageable toxicity in patients with early-stage TNBC [3]. The phase 3 KEYNOTE-522 trial (NCT03036488) evaluated the efficacy and safety of pemb...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on